Scindy Pharmaceutical (Suzhou) Co., Ltd. (referred to as "Scindy Pharmaceutical") unveiled a strategic collaboration with Suzhou GenePharma Co., Ltd. (Stock code: 430601, known as "GenePharma") on November 14, 2023. Chen Xiaobao, the founder and general manager of Scindy Pharmaceutical, and Dr. Zhang Peizhuo, chairman of GenePharma, graced the signing ceremony. This partnership intends to leverage GenePharma's expertise in siRNA technology alongside Scindy Pharmaceutical's prowess in LNP (Lipid Nanoparticle) development, fostering an extensive alliance to advance siRNA-LNP drug research and advancement.
Chen Xiaobao expressed pride in the collaboration, citing, "Our agreement with GenePharma marks a significant milestone. With our i-Core LNP? platform, Scindy Pharmaceutical delivers a comprehensive LNP carrier solution, enhancing small nucleic acid drug screening efficiency through our siRNA LNP transfection reagent. This collaboration allows us to fuse our strengths and drive RNAi drug innovation from its core."
Dr. Zhang Peizhuo highlighted GenePharma's specialization in small nucleic acid drug development and applauded Scindy Pharmaceutical's siRNA-LNP delivery technology as an additional asset for expanding the application and development of such drugs, offering more solutions to pharmaceutical clients.
About Scindy Pharmaceutical
Scindy Pharmaceutical, a research and development enterprise centered on independent innovation in nanocarriers, focuses on advancing innovative therapies like RNA through cutting-edge nanodelivery technology. The company's i-Core LNP? nanocarrier platform, driven by molecular simulation biocomputing, offers a full-range nanocarrier technology solution, spanning from LNP carriers to extrahepatic targeted delivery technology and pipeline development.
Since its inception in 2021, Scindy Pharmaceutical has concentrated on differentiated pipeline development in infectious and rare diseases. Leveraging its leading LNP platform, the company has launched novel LNP-based gene carrier products for cell and gene therapy.
About GenePharma
GenePharma, a frontrunner in China's RNA industry, stands as a key provider of RNA drug technology. Established in 2003 in Shanghai Zhangjiang High-tech Park, the company expanded to its headquarters in BioBAY, Suzhou Industrial Park, in 2007.
This pioneer in RNA research reagents and technical services boasts a global impact, with over 54,000 representative papers by scientists worldwide citing GenePharma's products and services in esteemed journals like Science, Cell, Nature Biotechnology, and more.
Moreover, GenePharma is dedicated to small nucleic acid drug transformation and R&D outsourcing services, securing 138 patents (17 PCT patents) and 82 authorized valid patents. With expansive scientific research facilities in Suzhou Industrial Park and Shanghai Zhangjiang High-tech Park, GenePharma leads in RNA drug development and pre-clinical research, offering services to various pharmaceutical companies.
In 2023, the company joined hands with the National Center of Technology Innovation for Biopharmaceuticals to establish a nucleic acid drug pilot test platform, catering to small nucleic acid drug research from discovery to development stages for pharmaceutical entities.
